Advances in the Diagnosis and Management of Persistent Pulmonary Hypertension of the Newborn

Pediatric Clinics of North America

Volumn 56, Issue 3, 2009, Pages 579-600

  Konduri, G Ganesh ^a   Kim, U Olivia ^a  

^a CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

Extracorporeal membrane oxygenation; Nitric oxide; Outcomes of persistent pulmonary hypertension of the newborn; Pulmonary hypertension; Respiratory failure in the newborn

Indexed keywords

ADRENALIN; ARGININE; ARTIFICIAL LUNG SURFACTANT; BETAMETHASONE; CARBON DIOXIDE; CYCLIC GMP; DNA; DOBUTAMINE; DOPAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTOXIN; ILOPROST; MILRINONE; MUSCLE RELAXANT AGENT; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PHOSPHODIESTERASE V; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SUPEROXIDE; SUPEROXIDE DISMUTASE; SURFACTANT PROTEIN B; THROMBOXANE; UNINDEXED DRUG; CARDIOTONIC AGENT; HYPNOTIC SEDATIVE AGENT;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; CYANOSIS; DEVELOPMENTAL DISORDER; DNA DETERMINATION; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SAFETY; ECHOCARDIOGRAPHY; EDEMA; EXTRACORPOREAL OXYGENATION; FOLLOW UP; GENE MUTATION; GESTATION PERIOD; GRAM NEGATIVE BACTERIUM; HEARING IMPAIRMENT; HUMAN; HYALINE MEMBRANE DISEASE; HYPOTENSION; INFANT MORTALITY; LUNG BIOPSY; LUNG CIRCULATION; LUNG DISEASE; LUNG HYPOPLASIA; LUNG VASCULAR RESISTANCE; MECONIUM ASPIRATION; MEDICAL ASSESSMENT; NEUROLOGIC DISEASE; NEWBORN; NONHUMAN; OXYGEN TENSION; OXYGENATION; PATHOPHYSIOLOGY; PERSISTENT PULMONARY HYPERTENSION; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRENATAL DRUG EXPOSURE; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; SEPSIS; STREPTOCOCCUS AGALACTIAE; SURVIVAL RATE; THERAPEUTIC HYPERVENTILATION; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VASOCONSTRICTION; VASODILATATION; DRUG CONTRAINDICATION; INCIDENCE; METHODOLOGY;

CARDIOTONIC AGENTS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; HYPNOTICS AND SEDATIVES; INCIDENCE; INFANT, NEWBORN; MECONIUM ASPIRATION SYNDROME; NITRIC OXIDE; PERSISTENT FETAL CIRCULATION SYNDROME; RESPIRATORY THERAPY;

EID: 67649130036     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.04.004     Document Type: Review

References (115)

1. Gersony W.M., Duc G.V., and Sinclair J.C. "PFC syndrome" (persistence of the fetal circulation). Circulation 40 Suppl 3 (1969) 87
2. Fox W.W., Gewitz M.H., Dinwiddie R., et al. Pulmonary hypertension in the perinatal aspiration syndromes. Pediatrics 59 2 (1977) 205-211
3. Hageman J.R., Adams M.A., and Gardner T.H. Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management. Am J Dis Child 138 6 (1984) 592-595
4. John E., Roberts V., and Burnard E.D. Persistent pulmonary hypertension of the newborn treated with hyperventilation: clinical features and outcome. Aust Paediatr J 24 6 (1988) 357-361
5. Davis J.M., Spitzer A.R., Cox C., et al. Predicting survival in infants with persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 5 1 (1988) 6-9
6. Konduri G.G., Solimano A., Sokol G.M., et al. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics 113 3 Pt 1 (2004) 559-564
7. Alameh J., Bachiri A., Devisme L., et al. Alveolar capillary dysplasia: a cause of persistent pulmonary hypertension of the newborn. Eur J Pediatr 161 5 (2002) 262-266
8. Kunig A.M., Parker T.A., Nogee L.M., et al. ABCA3 deficiency presenting as persistent pulmonary hypertension of the newborn. J Pediatr 151 3 (2007) 322-324
9. Dawes G.S., Mott J.C., Widdicomb J.G., et al. Changes in the lungs of the newborn lamb. J Physiol 121 (1953) 141-162
10. Cassin S., Dawes G.S., Mott J.C., et al. The vascular resistance of the foetal and newly ventilated lung of the lamb. J Physiol 171 (1964) 61-79
11. Lakshminrusimha S., and Steinhorn R.H. Pulmonary vascular biology during neonatal transition. Clin Perinatol 26 3 (1999) 601-619
12. Rasanen J., Wood D.C., Debbs R.H., et al. Reactivity of the human fetal pulmonary circulation to maternal hyperoxygenation increases during the second half of pregnancy: a randomized study. Circulation 97 3 (1998) 257-262
13. Morin F.C., Egan E.A., Ferguson W., et al. Development of pulmonary vascular response to oxygen. Am J Physiol 254 (1988) H542-H546
14. Velvis H., Moore P., and Heymann M.A. Prostaglandin inhibition prevents the fall in pulmonary vascular resistance as a result of rhythmic distension of the lungs in fetal lambs. Pediatr Res 30 (1991) 62-68
15. Walker A.M., Ritchie B.C., Adamson T.M., et al. Effect of changing lung liquid volume on the pulmonary circulation of fetal lambs. J Appl Physiol 64 1 (1988) 61-67
16. Abman S.H., Chatfield B.A., Hall S.L., et al. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 259 (1990) H1921-H1927
17. Tiktinsky M.H., and Morin III F.C. Increasing oxygen tension dilates fetal pulmonary circulation via endothelium-derived relaxing factor. Am J Physiol 265 1 Pt 2 (1993) H376-H380
18. Shaul P.W., and Wells L.B. Oxygen modulates nitric oxide production selectively in fetal pulmonary endothelial cells. Am J Respir Cell Mol Biol 11 4 (1994) 432-438
19. Shaul P.W., Campbell W.B., Farrar M.A., et al. Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase. J Clin Invest 90 6 (1992) 2147-2155
20. Konduri G.G., and Mattei J. Role of oxidative phosphorylation and ATP release in birth related pulmonary vasodilation in fetal lambs. Am J Physiol Heart Circ Physiol 283 4 (2002) H1600-H1608
21. Konduri G.G., Mital S., Gervasio C.T., et al. Purine nucleotides contribute to pulmonary vasodilation caused by birth related stimuli in the ovine fetus. (Heart Circ Physiol 41). Am J Physiol 272 (1997) H2377-H2384
22. Shaul P.W., Farrar M.A., and Magness R.R. Pulmonary endothelial nitric oxide production is developmentally regulated in the fetus and newborn. Am J Physiol 265 Heart Circ Physiol 34 (1993) H1056-H1063
23. Gien J., Seedorf G.J., Balasubramaniam V., et al. Intrauterine pulmonary hypertension impairs angiogenesis in vitro: role of vascular endothelial growth factor nitric oxide signaling. Am J Respir Crit Care Med 176 11 (2007) 1146-1153
24. Grover T.R., Parker T.A., Markham N.E., et al. rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep. Am J Physiol Lung Cell Mol Physiol 289 2 (2005) L315-L321
25. Matsushita T., Hislop A.A., Boels P.J., et al. Changes in ANP responsiveness of normal and hypertensive porcine intrapulmonary arteries during maturation. Pediatr Res 46 4 (1999) 411-418
26. Leffler C.W., Hessler J.R., and Green R.S. The onset of breathing at birth stimulates pulmonary vascular prostacyclin synthesis. Pediatr Res 18 10 (1984) 938-942
27. Cornfield D.N., Reeve H.L., Tolarova S., et al. Oxygen causes fetal pulmonary vasodilation through activation of a calcium-dependent potassium channel. Proc Natl Acad Sci U S A 93 (1996) 8089-8094
28. Archer S.L., Souil E., Dinh-Xuan A.T., et al. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 101 11 (1998) 2319-2330
29. Villanueva M.E., Zaher F.M., Svinarich D.M., et al. Decreased gene expression of endothelial nitric oxide synthase in newborns with persistent pulmonary hypertension. Pediatr Res 44 (1998) 338-343
30. Pearson D.L., Dawling S., Walsh W., et al. Neonatal pulmonary hypertension: urea-cycle intermediates, nitric oxide production and carbamoylphosphate synthetase function. N Engl J Med 344 24 (2001) 1832-1838
31. Shaul P.W., Yuhanna I.S., German Z., et al. Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol 272 Lung Cell Mol Physiol (1997) L1005-L1012
32. Villamor E., Le Cras T.D., Horan M.P., et al. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. Am J Physiol 272 Lung Cell Mol Physiol 16 (1997) L1013-L1020
33. Arrigoni F.I., Vallance P., Haworth S.G., et al. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 107 8 (2003) 1195-1201
34. Pullamsetti S., Kiss L., Ghofrani H.A., et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 19 9 (2005) 1175-1177
35. Rosenberg A.A., Kennaugh J., Koppenhafer S.L., et al. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J Pediatr 123 1 (1993) 109-114
36. Wedgwood S., and Black S.M. Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 288 3 (2005) L480-L487
37. Brennan L.A., Steinhorn R.H., Wedgwood S., et al. Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: a role for NADPH oxidase. Circ Res 92 6 (2003) 683-691
38. Konduri G.G., Bakhutashvili I., Eis A., et al. Oxidant stress from uncoupled nitric oxide synthase impairs vasodilation in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 292 4 (2007) H1812-H1820
39. Tzao C., Nickerson P.A., Russell J.A., et al. Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs. Pediatr Pulmonol 31 2 (2001) 97-105
40. Csaba I.F., Sulyok E., and Ertl T. Relationship of maternal treatment with indomethacin to persistence of fetal circulation syndrome. J Pediatr 92 3 (1978) 484
41. Rubaltelli F.F., Chiozza M.L., Zanardo V., et al. Effect on neonate of maternal treatment with indomethacin. J Pediatr 94 1 (1979) 161
42. Alano M.A., Ngougmna E., Ostrea E.M., et al. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 107 (2001) 519-523
43. Abman S.H., Shanley P.F., and Accurso F.J. Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest 83 (1989) 1849-1858
44. Morin F.C. Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in newborn lamb. Pediatr Res 25 (1989) 245-250
45. Konduri G.G., Ou J., Shi Y., et al. Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 285 1 (2003) H204-H211
46. Lakshminrusimha S., Russell J.A., Wedgwood S., et al. Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am J Respir Crit Care Med 174 12 (2006) 1370-1377
47. Grover T.R., Parker T.A., Balasubramaniam V., et al. Pulmonary hypertension impairs alveolarization and reduces lung growth in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 288 4 (2005) L648-L654
48. Danhaive O., Margossian R., Geva T., et al. Pulmonary hypertension and right ventricular dysfunction in growth-restricted, extremely low birth weight neonates. J Perinatol 25 7 (2005) 495-499
49. Walsh-Sukys M.C., Tyson J.E., Wright L.L., et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105 1 Pt 1 (2000) 14-20
50. Yoder B.A., Kirsch E.A., Barth W.H., et al. Changing obstetric practices associated with decreasing incidence of meconium aspiration syndrome. Obstet Gynecol 99 5 Pt 1 (2002) 731-739
51. Yoder B.A., Gordon M.C., and Barth Jr. W.H. Late-preterm birth: does the changing obstetric paradigm alter the epidemiology of respiratory complications?. Obstet Gynecol 111 4 (2008) 814-822
52. Dargaville P.A., South M., and McDougall P.N. Surfactant and surfactant inhibitors in meconium aspiration syndrome. J Pediatr 138 1 (2001) 113-115
53. Soukka H., Jalonen J., Kero P., et al. Endothelin-1, atrial natriuretic peptide and pathophysiology of pulmonary hypertension in porcine meconium aspiration. Acta Paediatr 87 4 (1998) 424-428
54. Radhakrishnan R.S., Lally P.A., Lally K.P., et al. ECMO for meconium aspiration syndrome: support for relaxed entry criteria. ASAIO J 53 4 (2007) 489-491
55. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354 6 (2006) 579-587
56. Andrade S.E., McPhillips H., Loren D., et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 18 3 (2009) 246-252
57. Shankaran S., Farooki Z.Q., and Desai R. Beta-hemolytic streptococcal infection appearing as persistent fetal circulation. Am J Dis Child 136 8 (1982) 725-727
58. Shook L.A., Pauly T.H., and Marple S.L. Group B Streptococcus promotes oxygen radical-dependent thromboxane accumulation in young piglets. Pediatr Res 27 4 Pt 1 (1990) 349-352
59. Navarrete C.T., Devia C., Lessa A.C., et al. The role of endothelin converting enzyme inhibition during group B Streptococcus-induced pulmonary hypertension in newborn piglets. Pediatr Res 54 3 (2003) 387-392
60. Heritage C.K., and Cunningham M.D. Association of elective repeat cesarian delivery and persistent pulmonary hypertension of the newborn. Am J Obstet Gynecol 152 (1985) 627-629
61. Bohn D. Congenital diaphragmatic hernia. Am J Respir Crit Care Med 166 (2002) 911-915
62. Boloker J., Bateman D.A., Wung J.T., et al. Congenital diaphragmatic hernia in 120 infants treated consecutively with permissive hypercapnea/spontaneous respiration/elective repair. J Pediatr Surg 37 3 (2002) 357-366
63. Singh S.A., Ibrahim T., Clark D.J., et al. Persistent pulmonary hypertension of newborn due to congenital capillary alveolar dysplasia. Pediatr Pulmonol 40 4 (2005) 349-353
64. Eulmesekian P., Cutz E., Parvez B., et al. Alveolar capillary dysplasia: a six-year single center experience. J Perinat Med 33 4 (2005) 347-352
65. Hamvas A., Cole F.S., and Nogee L.M. Genetic disorders of surfactant proteins. Neonatology 91 4 (2007) 311-317
66. Shulenin S., Nogee L.M., Annilo T., et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 350 13 (2004) 1296-1303
67. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 336 (1997) 597-604
68. Lotze A., Mitchell B.R., Bulas D.I., et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 132 (1998) 40-47
69. Hintz S.R., Suttner D.M., Sheehan A.M., et al. Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization. Pediatrics 106 6 (2000) 1339-1343
70. Kinsella J.P., Truog W.E., Walsh W.F., et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 131 (1997) 55-62
71. Cheung P.Y., Tyebkhan J.M., Peliowski A., et al. Prolonged use of pancuronium bromide and sensorineural hearing loss in childhood survivors of congenital diaphragmatic hernia. J Pediatr 135 (1999) 233-239
72. Robertson C., Tyberkhan J.M., and Peliowski A. Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure. Acta Pædiatr 95 (2006) 214-223
73. Drummond W.H., Gregory G.A., Heymann M.A., et al. The independent effects of hyperventilation, tolazoline, and dopamine on infants with persistent pulmonary hypertension. J Pediatr 98 4 (1981) 603-611
74. Schreiber M.D., and Soifer S.J. Respiratory alkalosis attenuates thromboxane-induced pulmonary hypertension. Crit Care Med 16 12 (1988) 1225-1228
75. 2, attenuates hypoxia-induced pulmonary vasoconstriction in newborn lambs. Pediatr Res 20 2 (1986) 113-117
76. Hendricks-Munoz K.D., and Walton J.P. Hearing loss in infants with persistent fetal circulation. Pediatrics 81 5 (1988) 650-656
77. Marron M.J., Crisafi M.A., Driscoll Jr. J.M., et al. Hearing and neurodevelopmental outcome in survivors of persistent pulmonary hypertension of the newborn. Pediatrics 90 3 (1992) 392-396
78. Tourneux P., Rakza T., Bouissou A., et al. Pulmonary circulatory effects of norepinephrine in newborn infants with persistent pulmonary hypertension. J Pediatr 153 3 (2008) 345-349
79. Frostell C., Fratacci M.D., Wain J.C., et al. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 83 6 (1991) 2038-2047 [erratum in: Circulation 1991;84(5):2212]
80. Williams O., Rafferty G.F., Hannam S., et al. Nasal and lower airway levels of nitric oxide in prematurely born infants. Early Hum Dev 72 1 (2003) 67-73
81. Leipala J.A., Williams O., Sreekumar S., et al. Exhaled nitric oxide levels in infants with chronic lung disease. Eur J Pediatr 163 (2004) 555-558
82. Roberts J.D., Polaner D.M., Lang P., et al. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340 8823 (1992) 818-819
83. Kinsella J.P., Neish S.R., Shaffer E., et al. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340 8823 (1992) 819-820
84. Roberts J.D., Fineman J.R., Morin F.C., et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 336 (1997) 605-610
85. Christou H., Van Marter L.J., Wessel D.L., et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Crit Care Med 28 11 (2000) 3722-3727
86. Clark R.H., Kueser T.J., Walker M.W., et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med 342 (2000) 469-474
87. Wessel D.L., Adatia I., Van Marter L.J., et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 100 5 (1997) E7
88. American Academy of Pediatrics Committee on Fetus and Newborn. Use of inhaled nitric oxide. Pediatrics 106 (2000) 344-345
89. Davidson D., Barefield E.S., Kattwinkel J., et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double masked, placebo controlled, dose-response, multicenter study. Pediatrics 101 (1998) 325-334
90. Christou H., Magnani B., Morse D.S., et al. Inhaled nitric oxide does not affect adenosine 5′-diphosphate-dependent platelet activation in infants with persistent pulmonary hypertension of the newborn. Pediatrics 102 (1998) 1390-1393
91. Sokol G.M., Fineberg N.S., and Wright L.L. Changes in arterial oxygen tension when weaning neonates from inhaled nitric oxide. Pediatr Pulmonol 32 1 (2001) 14-19
92. Davidson D., Barefield E.S., and Kattwinkel J. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 104 2 Pt 1 (1999) 231-236
93. Lakshminrusimha S., Russell J.A., Steinhorn R.H., et al. Pulmonary hemodynamics in neonatal lambs resuscitated with 21%, 50%, and 100% oxygen. Pediatr Res 62 3 (2007) 313-318
94. Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 99 (1997) 838-845
95. Hanson K.A., Ziegler J.W., Rybalkin S.D., et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 275 5 Pt 1 (1998) L931-L941
96. Atz A.M., and Wessel D.L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91 (1999) 307-310
97. Baquero H., Soliz A., Neira F., et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 117 4 (2006) 1077-1083
98. Travadi J.N., and Patole S.K. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 36 6 (2003) 529-535
99. Kelly L.K., Porta N.F., Goodman D.M., et al. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 141 6 (2002) 830-832
100. Chang A.C., Atz A.M., Wernovsky G., et al. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med 23 11 (1995) 1907-1914
101. Bassler D., Choong K., McNamara P., et al. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 89 1 (2006) 1-5
102. McNamara P.J., Laique F., Muang-In S., et al. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care 21 2 (2006) 217-222
103. Bartlett R.H., Gazzaniga A.B., Huxtable R.F., et al. Extracorporeal circulation (ECMO) in neonatal respiratory failure. J Thorac Cardiovasc Surg 74 6 (1977) 826-833
104. UK Collaborative ECMO Trial Group. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet 348 9020 (1996) 75-82
105. Mugford M., Elbourne D., and Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev 3 (2008) CD001340
106. Farrow K.N., Fliman P., and Steinhorn R.H. The disease treated with ECMO: focus on PPHN. Semin Perinatol 29 (2005) 8-14
107. Arul N., and Konduri G.G. Inhaled nitric oxide for preterm neonates. Clin Perinatol 36 1 (2009) 43-61
108. Khemani E., McElhinney D.B., Rhein L., et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 120 6 (2007) 1260-1269
109. Mourani P.M., Sontag M.K., Ivy D.D., et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 154 (2009) 379-384
110. Marsh C.S., Marden B., and Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol 88 2 (2004) 306-307
111. Konduri G.G., Vohr B., and Robertson C. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. J Pediatr 150 3 (2007) 235-240
112. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near term infants: neurodevelopmental follow-up of the Neonatal Inhaled Nitric Oxide Study Group (NINOS). J Pediatr 136 (2000) 611-617
113. Robertson C.M., Tyebkhan J.M., Hagler M.E., et al. Late-onset, progressive sensorineural hearing loss after severe neonatal respiratory failure. Otol Neurotol 23 3 (2002) 353-356
114. Lipkin P.H., Davidson D., Spivak L., et al. Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. J Pediatr 140 3 (2002) 306-310
115. Chandrasekar I., Eis A., and Konduri G.G. Betamethasone attenuates oxidant stress in endothelial cells from fetal lambs with persistent pulmonary hypertension. Pediatr Res 63 1 (2008) 67-72